The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Long-term data from AstraZeneca/Merck’s Lynparza shows survival benefit in ovarian cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Lynparza (olaparib) showed clinically meaningful survival benefit as first line therapy in certain patients with ovarian cancer, according to long-term data.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Enhertu demonstrated median PFS of 13.2 months in IHC 1+ or IHC 2+/ISH- metastatic breast cancer in phase III trial

Detailed positive results from the DESTINY-Breast06 phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy in patients with HR-positive, HER2-low metastatic breast cancer and the overall trial population (patients with HR-positive, HER2-low and HER2-ultralow [defined as IHC 0 with membrane staining] expression) following one or more lines of endocrine therapy. 
Clinical Roundup

Lifileucel + pembrolizumab show promise for advanced melanoma in data from phase II study

Iovance Biotherapeutics Inc. a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer, has updated clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, for the upcoming 2024 ASCO Annual Meeting. 
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account